within Pharmacolibrary.Drugs.ATC.L;

model L04AX09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 0.0006333333333333333,
    adminDuration  = 600,
    adminMass      = 231 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.072,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AX09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diroximel fumarate is an oral immunomodulatory drug used for the treatment of relapsing forms of multiple sclerosis (MS). It is a prodrug that is rapidly converted to monomethyl fumarate (MMF), the active metabolite which exerts anti-inflammatory and neuroprotective effects. It is an FDA- and EMA-approved medication as of 2019 and is currently in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers (fasted/fed), reporting on monomethyl fumarate (active metabolite) following 231 mg diroximel fumarate twice daily oral administration.</p><h4>References</h4><ol><li><p>Wang, Y, &amp; Bhargava, P (2020). Diroximel fumarate to treat multiple sclerosis. <i>Drugs of today (Barcelona, Spain : 1998)</i> 56(7) 431–437. DOI:<a href=&quot;https://doi.org/10.1358/dot.2020.56.7.3151521&quot;>10.1358/dot.2020.56.7.3151521</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32648853/&quot;>https://pubmed.ncbi.nlm.nih.gov/32648853</a></p></li><li><p>Rousseau, FS, et al., &amp; Berkovich, RR (2023). Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate). <i>Multiple sclerosis and related disorders</i> 70 104500–None. DOI:<a href=&quot;https://doi.org/10.1016/j.msard.2023.104500&quot;>10.1016/j.msard.2023.104500</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36645997/&quot;>https://pubmed.ncbi.nlm.nih.gov/36645997</a></p></li><li><p>Paik, J (2021). Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use. <i>CNS drugs</i> 35(6) 691–700. DOI:<a href=&quot;https://doi.org/10.1007/s40263-021-00830-z&quot;>10.1007/s40263-021-00830-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34057708/&quot;>https://pubmed.ncbi.nlm.nih.gov/34057708</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AX09;
